EsophyX® Z+ Acquisition Expands Merit’s Endotek® Portfolio

UNIQUE & INNOVATIVE THERAPEUTIC SOLUTION

The TIF 2.0 procedure reconstructs the anti-reflux barrier. Utilizing the EsophyX Z+ with SerosaFuse® Implantable Fasteners, it creates a standardized flap valve.⁵ Learn more >

REFERENCES

1. Delshad et al. 2020. “Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor—Refractory Symptoms.” Gastroenterology 158, no 5 (April): 1250 ̶ 61.e2. Accessed June 28, 2024. doi: 10.1053/j.gastro.2019.12.014. (PMID: 31866243)
     (Symptoms: 40% of US adults GERD symptoms [200M x 0.4 = 80M]); (PPI use: 68% of PPI users take it daily [10.5M]); (Refractory: persistent troublesome symptoms > 2 d/wk)

2. Trad et al. 2018. “The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-Effective.” Surgical Innovation 25, no. 2 (April): 149 ̶ 57. Accessed June 28, 2024. doi: 10.1177/1553350618755214. (PMID: 29405886)

3. Testoni et al. 2021. “Long-Term Outcomes of Transoral Incisionless Fundoplication for Gastro-Esophageal Reflux Disease: Systematic-Review and Meta-Analysis.” Endosc Int Open 9, no. 2 (February): E239 ̶ 46. Accessed June 28, 2024. doi: 10.1055/a-1322-2209. (PMID: 33553587)

4. Weighted Incidence Analysis of 13 TIF 2.0 Patient Cohorts’ GERD-HRQL, GERSS, and RSI Median Scores at Follow-up Intervals of > 6 mo, > 3 yr, and 5 yr.

5. EndoGastric Solutions®. 2023. “The EsophyX® Device: Making Transoral Reconstructive Surgery Possible.” Accessed June 28, 2024. https://www.endogastricsolutions.com/providers/tif-2-0-procedure/esophyx-device/